Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Adiso Therapeutics Announces Participation at Healthruption, Goldman Sachs Second Annual Healthcare Disruption Conference
By: PR Newswire Association LLC. - 31 Mar 2023Back to overview list

CONCORD, Mass., March 31, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced that Scott Megaffin, Chief Executive Officer, has been invited to join a panel discussion titled Inflammation & Immunology: Scratching the Surface of What's Next, at Goldman Sachs Second Annual Healthruption Conference, on Tuesday, April 4, 2023 at 3:00 p.m. ET in New York City.

About Adiso: 

Adiso is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients and their families by creating new and highly differentiated medicines to treat inflammatory diseases. This dedication is epitomized by our lead clinical candidates, ADS051, an oral, gut-restricted modulator of neutrophil trafficking and activation for the treatment of ulcerative colitis and ADS032, a dual NLRP3/NLRP1 inflammasome inhibitor initially being developed for inflammatory diseases of the lung. Adiso has built these development programs upon a rich history of institutional and academic collaboration, including the University of Massachusetts Chan Medical School, the Hudson Institute of Medical Sciences Centre for Innate Immunity and Infectious Diseases in Australia and the University of Edinburgh Centre for Inflammation Research. For more information, please visit http://www.adisotx.com and follow the company on LinkedIn.

Contacts 

Argot Partners 

Media: Sarah Sutton/Liza Sullivan 

IR: Jason Finkelstein 

Adiso@argotpartners.com 

212.600.1902 

Adiso Therapeutics, Inc. 

Jennifer Locke, Chief Operating & Business Officer 

pr@adisotx.com 

978.202.4335 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/adiso-therapeutics-announces-participation-at-healthruption-goldman-sachs-second-annual-healthcare-disruption-conference-301787114.html

SOURCE Adiso Therapeutics

Related companies:Adiso Therapeutics
Copyright 2023 PR Newswire Association LLC. Back to overview list
to the top ↑